RGCC ONCOTRACE
RGCC OncoTrace – Early Cancer Risk
Screening with Circulating Tumor Cells (CTCs)
A cutting-edge blood test to detect circulating tumor cells early — before symptoms appear
OncoTrace is a specialized blood test developed by RGCC Group (Research Genetic Cancer Center), designed to detect the presence of Circulating Tumor Cells (CTCs) — cancer cells that may have shed from a tumor and entered the bloodstream.
Unlike traditional imaging or biopsy, OncoTrace offers a non-invasive, early detection method to assess your risk of cancer recurrence or identify active cancer-related activity at a microscopic level — even before tumors are visible on scans
Benefits of OncoTrace
Empower Your Health with Knowledge
Whether you're seeking peace of mind, early answers, or ongoing monitoring, OncoTrace is a cutting-edge tool to help you take control of your health before cancer takes control of you
Non-invasive early detection of cancer cell activity
Monitors potential cancer recurrence in survivors
Guides future diagnostic decisions and follow-up testing
Offers peace of mind through advanced cellular screening
Complements functional and preventive health strategies
What to Expect
Simple blood draw by our doctor
Sample is sent to RGCC’s certified lab in Europe
Full results typically available in 2–3 weeks
Follow-up consultation with a medical professional to interpret and plan next steps